来曲唑可能作为高级别浆液性卵巢癌患者的有价值维持治疗
该研究利用TCGA PANCAN数据集分析ESR1表达(全癌种n=8901,HGSOC n=527),并通过免疫组化检测ER表达(n=4071),在独立匹配原发与复发HGSOC队列(n=80)中验证,最后对新诊断ER+ HGSOC患者提供来曲唑维持治疗。结果显示来曲唑维持治疗与显著延长的无复发生存间隔相关(24个月后来曲唑组60% vs 对照组38.5%,p=0.035),在联合贝伐珠单抗患者中亦观察到该效应(12个月无复发20.8% vs 来曲唑联合贝伐珠单抗组87.5%,p=0.026)。
要点
- HGSOC中ESR1表达水平与乳腺癌相似,ER在原发和复发HGSOC中均有强表达。
- 来曲唑维持治疗与显著延长的无复发生存间隔相关(24个月后60% vs 38.5%,p=0.035)。
- 来曲唑联合贝伐珠单抗组12个月无复发率为87.5%,对照组为20.8%(p=0.026)。
核心结论
- 原发性HGSOC的ESR1表达略高于乳腺癌,ER表达与乳腺癌相似,而来曲唑在HGSOC中显示出有用性,尤其在化疗耐药或残留病灶患者中。
研究设计与样本
- 研究利用TCGA PANCAN数据集评估ESR1表达(全癌种n=8901,HGSOC n=527),并通过免疫组化检测ER表达(n=4071),在独立匹配原发与复发HGSOC队列(n=80)中验证,最后对新诊断ER+ HGSOC患者提供来曲唑维持治疗。
主要发现
- ESR1在HGSOC中的表达水平与乳腺癌相似且强表达。
- 免疫组化显示原发和匹配复发HGSOC中ER均强表达,尤其在铂耐药亚组。
- 来曲唑维持治疗与显著延长的无复发生存间隔相关:24个月后来曲唑组60% vs 对照组38.5%(p=0.035);RFS:一名受试者达到IC50 vs 13.2个月。
- 在联合贝伐珠单抗患者中亦观察到效应:12个月无复发20.8% vs 来曲唑联合贝伐珠单抗组87.5%(p=0.026)。
临床怎么用
- 作者认为来曲唑在HGSOC中显示出有用性,尤其在化疗耐药或残留病灶患者中。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Endocrine therapy is used as maintenance in estrogen receptor (ER) positive breast cancers and has been proposed in low-grade serous ovarian cancers (LGSOC). Here we examine a rationale for its use as maintenance in high-grade serous ovarian cancers (HGSOC). METHODS: We accessed the TCGA PANCAN dataset to evaluate the expression of ESR1. ESR1 expression data on all cancers (n=8901) and HGSOC (n=527) were followed by investigation of ER expression via immunohistochemistry (IHC) (n=4071). The same was performed in an independent cohort for matched primary and recurrent HGSOC (n=80). Finally, newly diagnosed ER+ HGSOC patients were offered a maintenance therapy with Letrozole. RESULTS: ESR1 was strongly expressed in similar levels in HGSOC as in breast cancer. We found a strong ER expression via IHC in both the primary and matched recurrent HGSOC, particularly in the Platinum-resistant subgroup. The additional use of Letrozole as maintenance treatment was associated with a significantly prolonged recurrence free interval (after 24months 60% when taking Letrozole versus 38.5% in the control group; p=0.035; RFS: IC50 reached by one subject versus 13.2months). This effect was also present in patients treated additionally with Bevacizumab; 20.8% of patients had no recurrence after 12months compared to 87.5% when taking Letrozole in addition to Bevacizumab (p=0.026). CONCLUSIONS: Primary HGSOC have a slightly higher ESR1 than and a similar ER expression breast cancer where aromatase inhibitor maintenance is routine for decades. Here we demonstrate evidence for the usefulness of Letrozole in HGSOC, particularly in patients with chemotherapy resistance or residual disease.
引用
- Heinzelmann-Schwarz V, Knipprath Mészaros A, Stadlmann S, et al. Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients. Gynecol Oncol. 2017. PMID: 29157627. doi:10.1016/j.ygyno.2017.10.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。